MXPA97003548A - Process for purifying and isolating 2'-desoxy-2 ', 2'-difluoronucleosi - Google Patents

Process for purifying and isolating 2'-desoxy-2 ', 2'-difluoronucleosi

Info

Publication number
MXPA97003548A
MXPA97003548A MXPA/A/1997/003548A MX9703548A MXPA97003548A MX PA97003548 A MXPA97003548 A MX PA97003548A MX 9703548 A MX9703548 A MX 9703548A MX PA97003548 A MXPA97003548 A MX PA97003548A
Authority
MX
Mexico
Prior art keywords
mixture
formula
nucleoside
acid
enriched
Prior art date
Application number
MXPA/A/1997/003548A
Other languages
Spanish (es)
Other versions
MX9703548A (en
Inventor
Patton Kjell Douglas
Chou Tasen
Michelle Poteet Laurie
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/340,972 external-priority patent/US5606048A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MXPA97003548A publication Critical patent/MXPA97003548A/en
Publication of MX9703548A publication Critical patent/MX9703548A/en

Links

Abstract

The present invention describes a process for purifying and isolating a nucleoside enriched in the beta anomer, comprising: a) providing a mixture containing R "and a nucleoside enriched in the beta anomer, of the formula (IB), wherein each X is independently selected from hydroxy protecting groups, and R 'is a nucleobase of the formula (II), wherein W is an amino protecting group, and R "is a nucleobase of the formula (III), wherein W'es an amino-hydrogen protecting group, in a high-boiling solvent, b) dilute the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles, c) add the diluted reaction mixture to aqueous acid, and d) maintain the mixture prepared in this way at a temperature of 70 ° C to 100 ° C, until the product of formula IB has precipitated, where W is now

Description

PROCESS FOR PURIFYING AND ISOLATING 2'-DESOXY-2 ', 2'- DIFLUORONUCLEOSIDES TECHNICAL FIELD The present invention relates to the field of pharmaceutical chemistry, and provides a process for purifying and isolating 2'-deoxy-2 ', 2'-difluoronucleosides. BACKGROUND TECHNIQUE The continued interest in the synthesis of 2'-deoxynucleosides and their analogs is reflected in their successful use as therapeutic agents in viral and cancerous diseases. A critical step in the total synthesis of the 2'-deoxynucleosides is the purification and isolation of the desired form of the nucleoside beta-anomer. This is critical, because the processes for the synthesis of 2'-deoxynucleosides are typically non-stereoselective, and form a mixture of alpha and beta nucleosides. Vorbruggen, et al., J. Org. Chem., 41, 2084 (1976); M. Hofer, Chem.
Ber. , 93, 2777 (1960); Walker et al., Nucleic Acid Reswarch, 12, 6827 (1984); R. P. Hodge et al., J. Org. Chem., 56, 1553 (1991); Tann et al., J. Org. Chem., 50, 3644 (1985); Howell et al., J. Org. Chem., 53, 85 (1988) and the patent of E.U.A. No. 4,965,374, by Chou et al., Report several syntheses of a mixture of the alpha and beta anomers of deoxy nucleosides. Despite advances in the process of nucleoside synthesis, there continues to be a need for a process capable of efficiently purifying and isolating REF: 24420 2'-deoxy-2 ', 2'-difluoronucleosides enriched in the beta anomer in increased yields , wherein the difluoronucleosides have been synthesized in the absence of a catalyst. Accordingly, the object of the present invention is to provide a process for efficiently purifying and isolating 2'-deoxy-2 ', 2'-difluoronucleosides enriched in the beta anomer. Other objects and advantages of the present invention will become apparent from the following description of the embodiments. DESCRIPTION OF THE INVENTION This invention is a process for purifying and isolating a nucleoside enriched in the beta anomer, comprising: a) providing a mixture containing R "and a nucleoside enriched in the beta anomer, of the formula wherein each X is independently selected from hydroxy protecting groups, and R 'is a nucleobase of the formula: wherein W is an amino protecting group; and R "is a nucleobase of the formula: wherein W is an amino or hydrogen protecting group; in a high-bng solvent; b) diluting the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles; c) adding the diluted reaction mixture to aqueous acid; and d) keeping the acid mixture prepared in this manner at a temperature of from 70 ° C to 100 ° C, until the product of formula LB has precipitated, where W is now WAY TO CARRY OUT THE INVENTION throughout of this document, all temperatures are in degrees Celsius, all proportions, percentages and the like are by weight, and the units in all mixtures are in units of volume, except where otherwise indicated. The anomeric mixtures are expressed as a weight / weight ratio, or as a percentage. The term "alkyl" alone or in combination refers to straight chain, cyclic and branched aliphatic hydrocarbon groups, which preferably contain up to 7 carbon atoms, such as the methyl, ethyl, n-propyl, isopropyl, n-groups. butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl and the like, or substituted straight, cyclic or branched aliphatic hydrocarbons, such as chloroethyl, 1,2-dichloroethyl, and the like. The term "substituted", alone or in combination, refers to a substitution by one or more of the selected groups of cyano, halo, carboalkoxy, toluoyl, nitro, alkoxy, alkyl, and dialkylamino. The phrase "enriched in the anomer", alone or in combination, refers to an anomeric mixture wherein the ratio of a specified anomer is greater than 1: 1, and includes a substantially pure anomer. The hydroxy (X) protecting groups refer to hydroxy protecting groups known in the art, such as those described in Chapter 3 of Protective Groups in Organic Chemistry, McOmie Ed., Plenum Press, New York (1973), and Chapter 2 of Protective Groups in Organic Synthesis, Green, T. John Wiley and Sons, New York (1981). Preferred hydroxy protecting groups are the ester forming groups, such as formyl, acetyl, substituted acetyl, propionyl, butynyl, pivaloyl, 2-chloroacetyl, benzoyl, substituted benzoyl, phenoxycarbonyl, methoxyacetyl; carbonate derivatives such as phenoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, vinyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl and benzyloxycarbonyl; alkyl ether-forming groups, such as benzyl, diphenylmethyl, triphenylmethyl, t-butyl, methoxymethyl, tetrahydropyranyl, allyl, tetrahydrothienyl, 2-methoxyethoxymethyl; carbamates, such as N-phenylcarbamate and N-imidazolylcarbamate; most preferred are benzoyl, mono-substituted benzoyl and disubstituted benzoyl, acetyl, pivaloyl, triphenylmethyl ethers, and most preferred is benzoyl. The amino protecting groups (W) are selected from the group consisting of silylamine-forming groups, such as trialkylsilyl, which include trimethylsilyl; isopropyldialkylsilyl, alkyldiisopropylsilyl, triisopropylsilyl, 1,1,3,3-tetraisopropyldisiloxanyl, t-butyldialkylsilyl and t-butyldiarylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl; formyl, acetyl, benzoyl and pivalamide; groups that. they form ethers, such as methoxymethyl, t-butyl, benzyl, allyl and tetrahydropyranyl; A preferred amino protecting group is trirnethylsilyl. The first step in the process of the claimed invention is to provide a mixture containing R "and a nucleoside enriched in the beta anomer of the formula: wherein each X is independently selected from hydroxy protecting groups, and R 'is a nucleobase of the formula wherein W is an amino protecting group; and R "is a nucleobase of the formula wherein W is an amino or hydrogen protecting group; in a high boiling solvent. Such a mixture can be created in many different ways. Methods for synthesizing such a mixture are described and claimed in European Patent Application No. 93304817.5. Following certain processes (that do not use a catalyzer, using an excess of nucleobase R ", page 9 of EP 93304817. 5; and using a high boiling point solvent, page 10, lines 13-17) described in European Patent Application No. 93304817.5, it is possible to prepare the nucleosides enriched in the beta anomer, in an anomeric ratio of alpha to beta from above. from 1: 1 to less than or equal to 1: 9. A large excess of R "must be used to obtain these ratios The excess of R" is separated from the desired product by the process of the present invention. The high-boiling solvent is a solvent that has a boiling point above 70 ° C. The solvent with high boiling point is moderately polar, stable to acid and non-nucleophilic. Typical high-boiling solvents are aromatic haloalkyl, alkoxy and halo substituted aromatics solvents, and mixtures thereof. The preferred high-boiling solvents are 1,2-dichloroethane, 1,1,2-trichloroethane, glyma, diglyme, toluene, xylenes, anisole, dichlorobromomethane, chlorobenzene, dibromochloromethane, tribromomethane, dibromomethane, acetomitrile, propionitrile, dioxane and mixtures thereof, while the most preferred one is anisole. Once a mixture containing R "and the nucleoside enriched in the described beta anomer is provided, the process of the present invention proceeds as follows: First, the reaction mixture is diluted with an organic solvent with a boiling point greater than 60 ° C. Suitable solvents are from the classes of ethers, esters, and nitriles, the preferred examples being acetonitrile, ethyl acetate and tetrahydrofuran.The dilution is carried out at an elevated temperature, which may be the The organic solvent must be heated to an elevated temperature, too, and the temperature of both, the reaction mixture and the solvent should be in the range of 70 ° C to 110 ° C. The most preferred solvent is acetonitrile. The amount of organic solvent added is in the range from 1 mi to 5 ml per 1 gram of R "(protected or unprotected cytosine) used No particular maintenance period is required after dilution of the reaction mixture, the diluted mixture can be taken immediately to the next stage. The diluted reaction mixture is added to a large amount of aqueous acid at an elevated temperature The purpose of the aqueous acid is to dissolve the excess R "(protected or unprotected cytosine), which was used in the glycosylation reaction described in page 9 of the application of EP No. 93304817.5. Therefore, the amount and degree of acidity of the aqueous acid depends on the excess amount of R "(protected or unprotected cytosine) used in the reaction itself.In addition, the amount of aqueous acid also depends on the selection of the substance. acid used to prepare the aqueous acid The most preferred acid is hydrochloric acid, used in a concentration from 1 N to 6 N, more preferably 4 N. When this acid is used, and the amount of excess R "(cytosine protected or unprotected) is in the range from 5X to 20X, the amount of aqueous hydrochloric acid is from 3 ml to 5 ml per 1 gram of R "(protected or unprotected cytosine) used, however, other acids are also usable aqueous minerals and conditions, and may be preferred in various circumstances., mineral acid substances such as sulfuric acid, sulfurous acid, phosphoric acid, nitric acid, and phosphonic acid can be used if desired by the operator. The concentration of the acid can be varied rather widely, approximately in inverse proportion to the acceptable volume of the total isolation stage. In general, concentrations from 1 N to 10% in the aqueous acid can be used. The volume of aqueous acid must be optimized experimentally for the individual acid and the amount in the reaction mixture. The necessary experiments are very simple, requiring only that the operator make successive adjustments of the concentration and volume of the acid with the specific reaction mixture in use, observing the solubility of R "(protected or unprotected cytosine) in each case. Aqueous acid does not need to be hot when combined with the reaction mixture.The aqueous acid can be at room temperature, provided that the entire mixture is heated to a temperature in the range of 70 ° C to 100 ° C. it may be sufficient to bring the reaction mixture to that temperature, or it may be necessary in some cases to heat the mixture externally.In some cases, the heat of reaction is greater than 100 ° C, and thus, the reaction mixture must be cooled , so that it remains below 100 ° C. This is so because it is important that the temperature of the aqueous acid is not high that any of the protective groups is hydrolyzed prematurely at this stage of the process. When acetonitrile is used as the organic solvent, the most highly preferred temperature is from 70 ° C to 80 ° C. The acid mixture resulting from the addition of the diluted reaction mixture to the aqueous acid is maintained, preferably with moderate agitation, by a period of time The physical changes that occur during this maintenance period are the dissolution of the excess of R "(protected or unprotected cytosine) in the aqueous acid layer, and the precipitation of the desired beta-nucleoside, the precipitation is selective, and the alpha-nucleoside Undesirable remains largely dissolved in the organic layer.Thus, the acid mixture must be kept at a constant temperature, until these two physical changes have occurred.In general, a period from 10 minutes to 1 hour is adequate. With sufficient maintenance period, the precipitated beta-nucleoside is separated from the two liquid phases by filtration or centrifugation, and washed with additional aqueous acid.The filtration or centrifugation should be carried out at an approximately constant temperature, to prevent the R "Dissolved (protected or unprotected cytosine) is separated by precipitation from the solution.
The beta nucleoside isolated and purified in this manner may still have an amino protecting group (W) present, or the amino protecting group (W) may have been hydrolyzed, and replaced with a hydrogen atom. The beta nucleoside isolated and purified in the above manner is of superior purity, with respect to the alpha nucleoside, R "(protected or unprotected cytosine) and other impurities, and it is also found that the desired product is prepared in superior performance When the acid mixture has been filtered or centrifuged to extract the solid product, the organic and aqueous layers are separated from the filtrate.The excess of R "(protected or unprotected cytosine) is in the aqueous layer, and can be extracted from that layer and recycled back to the process. The R "(protected or unprotected cytosine) can be recovered by simply cooling the aqueous layer and filtering the precipitated R (protected or unprotected cytosine), or by making the aqueous layer basic, cooling the basic solution, and filtering to collect the R "precipitate (protected or unprotected cytosine) The cytosine recovered from the above process is routinely recycled to the process of making the mixture, as described in EP No. 93304817.5 Thus, the claimed process provides an economical recycling of R" ( protected or unprotected cytosine), which is a beneficial property of the process. The final phase of the process is the elimination of the protective groups X and any remaining W of the solid, purified blocked nucleoside of formula IB. The same anomeric unprotected nucleoside ratio is obtained by the removal of the protecting groups. Most silyl-amino protecting groups are easily hydrolyzed by the use of a protic solvent, such as water or an alcohol. Most silyl-amino protecting groups are vulnerable to hydrolysis during their contact with a mineral acid. Acyl protecting groups, such as benzoyl and acyl-amino protecting groups, are removed by hydrolysis with a strong base, at a temperature from 0 ° C to 100 ° C. Strong or moderately strong bases suitable for use in This reaction is the bases that have a pKa (at 25 ° C) from 8.5 to 20.0. Such bases include alkali metal hydroxides, such as sodium or potassium hydroxide; alkali metal alkoxides such as sodium methoxide or potassium t-butoxide; alkali metal amides; amines such as diethyl amine, hydroxylamine, ammonia and the like; and other common bases such as hydrazine and the like. At least one base equivalent is needed for each protective group. The acyl protecting groups can also be removed with acid catalysts, such as methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or with acidic ion exchange resins. It is preferred to carry out such hydrolysis at a relatively high temperature, such as the reflux temperature of the mixture, but temperatures as low as the environment can be used when particularly strong acids are used. Care must be taken to preserve these acyl protecting groups, so that they are not hydrolyzed prematurely during the early stages of the process of the invention. The removal of the ether protecting groups is carried out by known methods, for example, with ethanethiol and aluminum chloride. The protective group of t-butyldimethylsilyl requires acidic conditions, such as contact with a gaseous hydrogen halide, for its removal. The removal of the protecting groups can conveniently be carried out in alcoholic solvents, especially aqueous alkanols such as methanol. However, the deblocking reaction can also be carried out in any convenient solvent, such as polyoles including ethylene glycol, ethers such as tetrahydrofuran, ketones such as acetone and methyl ethyl ketone, or dimethylsulfide. In a preferred embodiment, the deblocking reaction employs ammonia to remove a benzoyl protecting group of hydroxy, at a temperature of 10 ° C. It is preferable, however, to use an excess of base in this reaction, although the amount of excess base used is not crucial. The nucleoside enriched in the resulting beta anomer or an organic or inorganic acid addition salt thereof, can be extracted and / or isolated from the reaction mixture by the process described in the patent of E.U.A. No. 4,965,374. The following example strates specific aspects of the present invention, and is not intended to limit the scope thereof in any respect, and should not be construed in this manner. Example 1 Preparation, purification and isolation of l- (2'-deoxy-2 ', 2'-difluoro-3', 5'-di-O-benzoyl-D-ribofuranosyl) -4-ammopyrimidin-2-one enriched in the beta anomer with 22.5 equivalents of bis-trimethylsilylcytosine To a 250 ml three-necked flask were added 30 g of cytosine, 25 mg of ammonium sulfate and 150 ml of hexamethyldisilazane, and the mixture was heated to 125 ° C, and maintained for 30 minutes after the dissolution of all solids. Then, the temperature was raised to 145 ° C, held until the boiling stopped, and then kept at 120 ° C under vacuum until solids began to form above the level of the liquid in the flask. Then the mixture was cooled to 105 ° C, and 25 ml of anisole were added. In another 125 ml flask, 10 ml of anisole and 5.75 g of 2-deoxy-2,2-difluoro-3,5-dibenzoyl-D-ribofuranosyl-methanesulfonate were combined, and the mixture was heated until an homogeneous liquid. That liquid was added at constant temperature to the cytosine mixture, and the combined mixture was maintained at 100 ° C for 24 hours. A portion of 133 ml of 4 N hydrochloric acid was placed in a 500 ml flask. A 31.3 ml portion of acetomtril was added to the reaction mixture, and the diluted reaction mixture was then poured over the acid with constant stirring, while a cooling bath was applied to the 500 ml flask. The combined mixture was then stirred at 70 ° C for 10 minutes, and then filtered at a constant temperature. The wet cake was then suspended for 10 minutes at 70 ° C with 25 ml of 4N hydrochloric acid, and filtered again. The filter cake was suspended for 10 minutes at 70 ° C with 25 ml of deionized water, filtered, and the wet cake was suspended again at 70 ° C with 50 ml of deionized water. The pH of the aqueous suspension was brought to 7 with sodium bicarbonate, and the mixture was stirred for 10 minutes at 50 ° C or a higher temperature, and filtered again. The filter cake was suspended once more with 50 ml of deionized water at 70 ° C for 10 minutes, filtered, and the filter cake was dried and analyzed. It weighed 3.98 g, representing an isolated yield of 61 percent, and contained less than 1 percent of the unwanted alpha-anomer. The present invention has been described in detail, including preferred embodiments thereof. However, it wbe appreciated that those skd in the art, with consideration of the present disclosure, may make modifications and / or improvements on this invention that fall within the scope and spirit of the invention, as set forth in the following claims.
It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Having described the invention as above, property is claimed as contained in the following:

Claims (8)

  1. CLAIMS 1. A process for purifying and isolating a nucleoside enriched in the beta anomer, characterized in that it comprises: a) providing a mixture containing R "and a nucleoside enriched in the beta anomer, of the formula wherein each X is independently selected from hydroxy protecting groups, and R 'is a nucleobase of the formula: wherein W is an amino protecting group; and R "is a nucleobase of the formula: wherein W is an amino or hydrogen protecting group; in a high-boiling solvent; b) diluting the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles; c) adding the diluted reaction mixture to aqueous acid; and d) keeping the acid mixture prepared in this manner at a temperature from 70 ° C to 100 ° C, until the product of formula LB has precipitated, where W is now W \
  2. 2. A process according to claim 1, characterized in that the reaction mixture is diluted with acetonitrile, ethyl acetate and tetrahydrofuran.
  3. 3. A process according to claim 2, characterized in that the reaction mixture is diluted with acetonitrile
  4. 4. A process according to claim 1, characterized in that the aqueous acid is hydrochloric acid from 1 N to 6 N.
  5. 5. A process according to claim 1, characterized in that the acid mixture is stirred while the product is precipitating.
  6. 6. A process according to claim 1, characterized in that it additionally includes unblocking the product of formula IB purified to form the nucleoside, which is l- (2'-deoxy-2 ', 2'-difluoro-D-ribofuranosyl-4-) aminopyrimidin-2-one
  7. 7. A process for purifying a nucleoside enriched in the beta anomer substantially as described above with reference to the example
  8. 8. A process for purifying a nucleoside enriched in the beta anomer substantially as described above with reference to the examples, characterized in that it additionally comprises: (e) recovering R "to recycle it.
MX9703548A 1994-11-17 1995-11-01 Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides. MX9703548A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/340,972 US5606048A (en) 1992-06-22 1994-11-17 Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US08340972 1994-11-17
PCT/US1995/014086 WO1996016072A1 (en) 1994-11-17 1995-11-01 Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides

Publications (2)

Publication Number Publication Date
MXPA97003548A true MXPA97003548A (en) 1997-08-01
MX9703548A MX9703548A (en) 1997-08-30

Family

ID=23335711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703548A MX9703548A (en) 1994-11-17 1995-11-01 Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides.

Country Status (34)

Country Link
US (1) US5606048A (en)
EP (1) EP0712860B1 (en)
JP (1) JPH10509170A (en)
KR (1) KR100424990B1 (en)
CN (1) CN1044119C (en)
AR (1) AR001045A1 (en)
AT (1) ATE210142T1 (en)
AU (1) AU702588B2 (en)
BG (1) BG62737B1 (en)
BR (1) BR9509904A (en)
CA (1) CA2205350C (en)
CO (1) CO4600741A1 (en)
CZ (1) CZ292013B6 (en)
DE (1) DE69524365T2 (en)
DK (1) DK0712860T3 (en)
ES (1) ES2164745T3 (en)
HU (1) HU219019B (en)
IL (1) IL115854A (en)
MX (1) MX9703548A (en)
MY (1) MY115183A (en)
NO (1) NO308305B1 (en)
NZ (1) NZ296712A (en)
PE (1) PE50196A1 (en)
PL (1) PL182052B1 (en)
PT (1) PT712860E (en)
RO (1) RO118296B1 (en)
RU (1) RU2161622C2 (en)
SI (1) SI0712860T1 (en)
SK (1) SK283160B6 (en)
TW (1) TW377356B (en)
UA (1) UA53614C2 (en)
WO (1) WO1996016072A1 (en)
YU (1) YU49446B (en)
ZA (1) ZA959321B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (en) * 2000-05-26 2007-05-16 艾登尼科斯(开曼)有限公司 Methods and compositions for treating flaviviruses and pestiviruses
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2003059339A1 (en) * 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CN1678326A (en) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
CA2506129C (en) * 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EP2319853B1 (en) * 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US7214791B2 (en) * 2004-07-01 2007-05-08 Shenzhen Hande Technology Co., Ltd. Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material
JP2007522151A (en) * 2004-12-08 2007-08-09 シコール インコーポレイティド Difluoronucleoside and process for preparing the same
WO2006071090A1 (en) * 2004-12-30 2006-07-06 Hanmi Pharm. Co., Ltd. Method for the preparation of 2'-deoxy-2',2'-difluorocytidine
WO2006070985A1 (en) * 2004-12-30 2006-07-06 Hanmi Pharm. Co., Ltd. METHOD FOR THE PREPARATION OF 2#-DEOXY-2#,2#-DIFLUOROCYTIDINE
UA88940C2 (en) * 2005-03-04 2009-12-10 Дабур Фарма Лимитед Intermediate, process for preparing thereof and stereoselective glycosylation process
JP4516863B2 (en) * 2005-03-11 2010-08-04 株式会社ケンウッド Speech synthesis apparatus, speech synthesis method and program
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
BRPI0610950A2 (en) * 2005-06-03 2010-08-03 Scinopharm Taiwan Ltd process for producing an alpha anomer-enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate, and use thereof for producing a beta nocleoside
US8193354B2 (en) 2005-10-28 2012-06-05 Arch Pharmalabs Limited Process for preparation of Gemcitabine hydrochloride
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US20090069557A1 (en) * 2006-02-06 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of gemcitabine
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (en) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
JP5349342B2 (en) * 2007-03-23 2013-11-20 ドンウ シンテック カンパニー リミテッド Method for producing 2'-deoxy-2 ', 2'-difluorocytidine
CN100475832C (en) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 Novel highly-solid selectively synthesizing gemcitabine process and intermediate
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
EP2050757A1 (en) 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
TW200942231A (en) * 2008-01-11 2009-10-16 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
CN102066398B (en) * 2008-04-18 2014-09-10 里亚塔医药公司 Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
CN103588678A (en) 2008-04-18 2014-02-19 里亚塔医药公司 Compound including an anti-inflammatory pharmacore and method of use
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
PT2276493T (en) 2008-04-18 2019-01-10 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
KR101713140B1 (en) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
WO2010011782A1 (en) * 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
ES2628609T3 (en) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
JO3197B1 (en) * 2009-04-06 2018-03-08 Otsuka Pharma Co Ltd (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
EP2416780B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3721664A (en) * 1970-01-27 1973-03-20 Hoffmann La Roche Preparation of 5-cytosine nucleosides
DE2628202A1 (en) * 1976-06-23 1977-12-29 Max Planck Gesellschaft PROCESS FOR THE PREPARATION OF 2'-SUBSTITUTE-D-RIBOFURANOSYLPURINE DERIVATIVES
DE2721466A1 (en) * 1977-05-12 1978-11-16 Robugen Gmbh PROCESS FOR THE PREPARATION OF 2'-DESOXYRIBOFURANOSYL NUCLEOSIDES
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
FR2531962B1 (en) * 1982-08-17 1986-11-14 Sandoz Sa NOVEL DESOXYURIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0339161A1 (en) * 1988-04-01 1989-11-02 Merrell Dow Pharmaceuticals Inc. Novel fluorophosphonate nucleotide derivatives
JPH0232093A (en) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc Anti-retrovirus difluorinated nucleoside
HU906976D0 (en) * 1989-11-13 1991-05-28 Bristol Myers Squibb Co Process for producing 2', 3'-didesoxy-2'-fluoarabinonucleoside analogues
US5175267A (en) * 1990-03-02 1992-12-29 University Of Georgia Research Foundation, Inc. Stereoselective glycosylation of hetercyclic bases
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
UA41261C2 (en) * 1992-06-22 2001-09-17 Елі Ліллі Енд Компані METHOD OF OBTAINING BETA-ANOMER-ENRICHED NUCLEOSIDES
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides

Similar Documents

Publication Publication Date Title
EP0712860B1 (en) Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides
MXPA97003548A (en) Process for purifying and isolating 2'-desoxy-2 ', 2'-difluoronucleosi
US5426183A (en) Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
AU689674B2 (en) Process for preparing 1-(2'-deoxy-2',2'-difluoro-d-ribofuranosyl-4-aminopyrimidin- 2-one) hydrochloride
EP0577304B1 (en) Stereoselective anion glycosylation process
AU2005320374B2 (en) Method for the preparation of 2'-deoxy-2',2'-difluorocytidine
JP3653292B2 (en) Mass production of 2 ', 3'-didehydro-3'-deoxythymidine (d4T) using 5-methyluridine
RU2360919C2 (en) Method of obtaining 2'-desoxy-2', 2'-difluorocytidine
EP0193903A2 (en) Production of cytosine nucleosides
US6972330B2 (en) Chemical synthesis of methoxy nucleosides
JP5091126B2 (en) Process for the preparation of α-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and its use for preparing β-nucleosides
AU659008B2 (en) Stereoselective anion glycosylation process
US20030162957A1 (en) Protected deoxyadenosines and deoxyguanosines
WO2002068437A9 (en) Protected deoxyadenosines and deoxyguanosines